Nuveen’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-164,529
Closed -$7.81M 3251
2025
Q3
$7.81M Sell
164,529
-202,240
-55% -$9.79M ﹤0.01% 1692
2025
Q2
$19.6M Buy
366,769
+58,443
+19% +$2.66M 0.01% 1111
2025
Q1
$1.67M Buy
308,326
+136,808
+80% +$5.8M ﹤0.01% 2413
2024
Q4
$4.77M Sell
171,518
-3,385
-2% -$103K ﹤0.01% 2007
2024
Q3
$5.02M Hold
174,903
﹤0.01% 1985
2024
Q2
$4.1M Buy
174,903
+30,040
+21% +$642K ﹤0.01% 2051
2024
Q1
$3.66M Buy
144,863
+12,722
+10% +$306K ﹤0.01% 2128
2023
Q4
$3.09M Buy
132,141
+658
+0.5% +$13K ﹤0.01% 2211
2023
Q3
$6.65M Buy
131,483
+7,591
+6% +$353K ﹤0.01% 1719
2023
Q2
$5.78M Buy
123,892
+31,513
+34% +$1.44M ﹤0.01% 1835
2023
Q1
$3.53M Sell
92,379
-8,139
-8% -$363K ﹤0.01% 2079
2022
Q4
$1.23M Sell
100,518
-31,727
-24% -$1.36M ﹤0.01% 2599
2022
Q3
$1.62M Buy
132,245
+34,800
+36% +$532K ﹤0.01% 2510
2022
Q2
$921K Buy
97,445
+13,880
+17% +$145K ﹤0.01% 2821
2022
Q1
$1.2M Buy
83,565
+936
+1% +$16.4K ﹤0.01% 2742
2021
Q4
$1.62M Sell
82,629
-6,311
-7% -$140K ﹤0.01% 2666
2021
Q3
$2.21M Sell
88,940
-5,384
-6% -$122K ﹤0.01% 2622
2021
Q2
$2.34M Buy
94,324
+43,958
+87% +$1.23M ﹤0.01% 2632
2021
Q1
$1.46M Sell
50,366
-939
-2% -$28.4K ﹤0.01% 2756
2020
Q4
$1.32M Sell
51,305
-17,519
-25% -$487K ﹤0.01% 2696
2020
Q3
$2.12M Buy
68,824
+24,133
+54% +$843K ﹤0.01% 2354
2020
Q2
$1.11M Buy
44,691
+26,915
+151% +$615K ﹤0.01% 2580
2020
Q1
$377K Buy
+17,776
New +$381K ﹤0.01% 2867

Other funds holding AKRO

Nuveen's AKRO Position: Q4 2025 in Review

Nuveen sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 164,529 shares — an estimated $7.81M sold.

Nuveen first reported a position in AKRO in Q1 2020 and held it in 23 quarters. The position peaked at $19.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Nuveen reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nuveen sold 164,529 Akero Therapeutics shares in Q4 2025, an estimated $7.81M.
  • Nuveen first reported a position in Akero Therapeutics in Q1 2020 and held it in 23 quarters.
  • Nuveen's Akero Therapeutics position peaked at $19.6M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Nuveen's 13F filing for Q4 2025, filed 12 Feb 2026.